节点文献

新抗肿瘤药甘磷酰芥二期临床试用总结

Clinical Phase II Trial of a New Antineopiastlc Drug - Glyciphosphoramide

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 孙燕

【Author】 Cooperative Group for Clinical Study of Glyciphosphoramide Sun Yan

【机构】 中国医学科学院甘磷酰芥临床试用协作组

【摘要】 1965~1979年,23个单位用甘磷酰芥全身及局部给药法治疗301例肿瘤病人,完全缓解17例,部分缓解119例,有效率45.2%;口服对恶性淋巴瘤、乳腺癌和肺小细胞癌有效,对子宫肉瘤、白血病等也有一定疗效;喷敷或涂抹对乳腺癌等癌性溃疡效果显著。其主要毒性为消化道反应及骨髓抑制。影响疗效因素是病理类型、既往治疗、给药剂量及骨髓抑制与否。

【Abstract】 Clinical phase II trial of a new alkylating agent, glyciphosphoramide(GPM), ynthesized by Institute of Materia Medica, CAMS, was carried out cooperatively since 1965. 301 cases of advanced cancer were treated with GPM. Results showed that the effect was excellent in malignant lymphoma, breast cancer and small cell carcinoma of lung and apparent in a few cases of uterine sarcoma,acute and chronic leukemias, embryonal testicular carcinoma and nasopha-ryngeal cancer. Favorable results in the management of ulceration due to breast cancer and carcinoma of uterine cervix with topical application of GPM were also obtained.

  • 【文献出处】 中国医学科学院学报 ,Acta Academiae Medicinae Sinicae , 编辑部邮箱 ,1984年04期
  • 【下载频次】30
节点文献中: 

本文链接的文献网络图示:

本文的引文网络